Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
US7511057B2 · kind B2 · utility
10Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2005 |
| Grant date | Mar 31, 2009 |
| Priority date | — |
| Expiry date | Jun 3, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof;and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.